Tanvex BioPharma Balance Sheet Health
Financial Health criteria checks 5/6
Tanvex BioPharma has a total shareholder equity of NT$821.1M and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$2.8B and NT$1.9B respectively.
Key information
0%
Debt to equity ratio
NT$0
Debt
Interest coverage ratio | n/a |
Cash | NT$380.75m |
Equity | NT$821.11m |
Total liabilities | NT$1.94b |
Total assets | NT$2.76b |
Financial Position Analysis
Short Term Liabilities: 6541's short term assets (NT$604.2M) exceed its short term liabilities (NT$363.7M).
Long Term Liabilities: 6541's short term assets (NT$604.2M) do not cover its long term liabilities (NT$1.6B).
Debt to Equity History and Analysis
Debt Level: 6541 is debt free.
Reducing Debt: 6541 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6541 has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 6541 is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.